Expired activity
Please go to the PowerPak homepage and select a course.

Assessing Antibiotic Pharmacology and Susceptibility to Guide Selection and Improve Outcomes

This educational activity is sponsored by the Academy for Continued Healthcare Learning (ACHL) and supported by an educational grant from Merck & Company.


George H. Karam, MD
Paula Garvey Manship Chair of Medicine
Head of the LSUHSC Dept. of Internal Medicine
Louisiana State University
Baton Rouge, LA

James Lewis, II, PharmD, FIDSA
Infectious Disease Clinical Pharmacy Supervisor
Co-Director of Antibiotic Stewardship
Department of Pharmacy
Oregon Health & Science University
Portland, OR

Jason M. Pogue, PharmD, BCPS‐ID
Clinical Pharmacist, Infectious Diseases
Sinai‐Grace Hospital
Detroit Medical Center
Clinical Assistant Professor of Medicine
Wayne State University School of Medicine
Detroit, MI

Patricia (Trish) Simner, PhD, D(ABMM)
Director of Medical Bacteriology and Parasitology Laboratories
Associate Professor of Pathology
Johns Hopkins School of Medicine
Baltimore, MD


The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in a CPE activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been resolved prior to this CPE activity.

The following financial relationships have been provided:

George H. Karam, MD
Advisory Board: Merck, Paratek, and Shionogi
Consultant: Shionogi and Tetraphase
Honoraria Recipient: Merck

James S. Lewis II, PharmD, FIDSA
Consultant: Merck and Tetraphase

Jason M. Pogue, PharmD
Consultant: Melinta, Merck, Nabriva, Shionogi, and Tetraphase
Speakers Bureau: Melinta and Merck
Grant Support: Merck

Patricia J. Simner, MSc, PhD:
Consultant: Accelerate Diagnostics, CosmosID, OpGen Inc., and Roche Diagnostics
Research Grants: Accelerate Diagnostics, Affinity Biosensors, Check-Points BV, Hardy Diagnostics, and OpGen Inc.

Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: Novel antibiotics and available antibiotics under investigation for use in different types of serious infections.


acpeThe Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
UAN: 0396-0000-19-007-H04-P
Credits: 0.75 hour (0.075 ceu)

Type of Activity: Knowledge
Media: Internet
Estimated time to complete activity: 45 minutes


June 28, 2019


June 28, 2020


This activity is intended for ID pharmacists and other clinicians who care for patients with serious infections.


To receive credit, participants are required to view the online activity and complete the posttest and evaluation. To receive credit, 75% must be achieved on the posttest. There is no fee to participate in the activity. To receive credit, you must provide your date of birth and NABP number. All credit information will be uploaded into CPE monitor within 30 days.

For questions, contact Katlyn Cooper at kcooper@achlcme.org


James Lewis, PharmD presents two patient cases relating to the assessment and treatment of serious infections caused by Gram-negative pathogens. A faculty panel from MAD-ID 2019 provide supplemental background and discussions on the application of local antibiotic susceptibility tests, PK/PD drug profiles, and selection of antimicrobial therapy to improve outcomes. The purpose of this activity is to provide pharmacists, who care for patients with serious infections with the latest data on antimicrobial stewardship, available and emerging antibiotics against Gram-negative pathogens, and the optimization of therapy to improve outcomes and reduce resistance.

I. VAP/HAP: Case Presentation
II. Challenges with P. aeruginosa
III. Ensuring Effectiveness of Antibiotics and Reducing Resistance
IV. New and Emerging Approaches to Gram-negative Organisms
V. Antimicrobial Susceptibility Testing
VI. Molecular Epidemiology of Antibiotic Resistance
VII. cUTIs: Case Presentation


Upon completion of this activity, participants will be able to:

  • Demonstrate an understanding of the molecular epidemiology of antibiotic resistance in bacterial pathogens
  • Summarize the salient features and critical differences between the antibiotics currently in development for use against Gram-negative pathogens
  • Describe strategies to optimize antimicrobial therapy to ensure effectiveness of antibiotics and reduce resistance


Please ensure the computer system you plan to use meets the following minimum requirements:

  • Operating System: Windows 98 or higher & Macintosh 2.2 or higher
  • Internet Browser (Mac &/Windows): Internet Explorer 6.0 or higher, Google Chrome, Safari 5.0.6 or higher, Firefox 3.0.3 or higher & Opera 5 or higher
  • Broadband Internet connection: Cable, High-speed DSL & any other medium that is internet accessible
  • Peripherals: Computer speakers or headphones
  • Monitor Screen Resolution: 320 x 480 or higher
  • Media Viewing Requirements: Adobe Reader, Microsoft PowerPoint, Flash Player & HTML5


The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.

This educational activity was planned and produced in accordance with the ACPE Accreditation Standards for Continuing Pharmacy Education. Recommendations involving clinical medicine in a continuing education (CPE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CPE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.

This CPE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers' prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.